Revolution Net Tangible Assets vs Capital Surpluse Analysis
| RVMD Stock | USD 58.58 0.05 0.09% |
Revolution Medicines financial indicator trend analysis is much more than just breaking down Revolution Medicines prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Revolution Medicines is a good investment. Please check the relationship between Revolution Medicines Net Tangible Assets and its Capital Surpluse accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.
Net Tangible Assets vs Capital Surpluse
Net Tangible Assets vs Capital Surpluse Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Revolution Medicines Net Tangible Assets account and Capital Surpluse. At this time, the significance of the direction appears to have totally related.
The correlation between Revolution Medicines' Net Tangible Assets and Capital Surpluse is 0.99. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Revolution Medicines, assuming nothing else is changed. The correlation between historical values of Revolution Medicines' Net Tangible Assets and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Revolution Medicines are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Net Tangible Assets i.e., Revolution Medicines' Net Tangible Assets and Capital Surpluse go up and down completely randomly.
Correlation Coefficient | 0.99 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Capital Surpluse
Most indicators from Revolution Medicines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Revolution Medicines current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.At present, Revolution Medicines' Sales General And Administrative To Revenue is projected to slightly grow based on the last few years of reporting.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 929K | 9.2M | 47.5M | 49.9M | Net Interest Income | 917K | 9.2M | 47.2M | 49.5M |
Revolution Medicines fundamental ratios Correlations
Click cells to compare fundamentals
Revolution Medicines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Revolution Medicines fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 220.5M | 567.4M | 738.0M | 811.9M | 2.1B | 2.2B | |
| Other Current Liab | 14.4M | 18.8M | 21.5M | 22.7M | 67.3M | 70.7M | |
| Total Current Liabilities | 43.1M | 47.2M | 18.9M | 62.0M | 143.9M | 151.0M | |
| Total Stockholder Equity | 152.5M | 474.7M | 602.6M | 685.2M | 1.8B | 1.9B | |
| Other Liab | 24.9M | 16.6M | 14.7M | 7.3M | 6.6M | 6.3M | |
| Net Tangible Assets | (229.2M) | 399.1M | 528.1M | 611.8M | 703.5M | 738.7M | |
| Property Plant And Equipment Net | 7.1M | 36.3M | 71.2M | 73.7M | 100.0M | 105.0M | |
| Net Debt | (16.5M) | (71.6M) | (41.9M) | (97.2M) | (608.2M) | (577.8M) | |
| Retained Earnings | (157.4M) | (265.5M) | (452.6M) | (701.3M) | (1.1B) | (1.1B) | |
| Accounts Payable | 11.4M | 12.6M | 14.1M | 21.3M | 61.8M | 64.9M | |
| Cash | 16.7M | 104.3M | 108.5M | 161.4M | 696.1M | 731.0M | |
| Non Current Assets Total | 86.5M | 113.3M | 160.9M | 151.7M | 182.4M | 123.5M | |
| Non Currrent Assets Other | (8.3M) | (19.1M) | (14.5M) | (23.4M) | 10.1M | 10.6M | |
| Other Assets | 2.8M | 1.4M | 2.5M | 4.6M | 1.0 | 0.95 | |
| Cash And Short Term Investments | 122.8M | 440.7M | 577.1M | 644.9M | 1.9B | 1.9B | |
| Common Stock Shares Outstanding | 59.0M | 66.6M | 72.8M | 80.6M | 113.1M | 73.1M | |
| Liabilities And Stockholders Equity | 220.5M | 567.4M | 738.0M | 811.9M | 2.1B | 2.2B | |
| Non Current Liabilities Total | 24.9M | 45.5M | 116.5M | 64.8M | 91.7M | 61.2M | |
| Capital Surpluse | 1.3M | 4.7M | 740.1M | 1.1B | 1.2B | 1.3B | |
| Capital Lease Obligations | 172K | 32.7M | 66.6M | 64.2M | 87.9M | 92.3M | |
| Other Current Assets | 2.5M | 7.0M | 6.8M | 10.6M | 25.1M | 26.3M | |
| Other Stockholder Equity | 4.7M | 740.1M | 1.1B | 1.4B | 3.0B | 3.1B | |
| Total Liab | 68.0M | 92.7M | 135.4M | 126.7M | 235.5M | 247.3M | |
| Net Invested Capital | (152.6M) | 474.7M | 602.6M | 685.2M | 1.8B | 1.9B | |
| Property Plant And Equipment Gross | 7.1M | 36.3M | 82.0M | 88.2M | 117.7M | 123.6M | |
| Total Current Assets | 134.0M | 454.1M | 577.1M | 660.2M | 1.9B | 2.0B | |
| Accumulated Other Comprehensive Income | 74K | 116K | (376K) | (1.8M) | 544K | 571.2K | |
| Non Current Liabilities Other | 655K | 38.1M | 634K | 301K | 1.5M | 1.4M | |
| Net Working Capital | 90.9M | 406.9M | 558.1M | 598.2M | 1.7B | 1.8B | |
| Property Plant Equipment | 7.1M | 8.9M | 71.2M | 73.7M | 84.8M | 89.0M | |
| Short Long Term Debt Total | 172K | 32.7M | 66.6M | 64.2M | 87.9M | 46.2M | |
| Current Deferred Revenue | 17.1M | 20.6M | 18.9M | 4.5M | (54.6M) | (51.8M) | |
| Net Receivables | 8.7M | 6.4M | 5.9M | 4.7M | 1.3M | 1.2M | |
| Capital Stock | 305.1M | 7K | 8K | 9K | 16K | 15.2K | |
| Short Term Debt | 172K | 3.7M | 12.4M | 13.5M | 14.7M | 8.2M | |
| Intangible Assets | 62.0M | 60.9M | 59.9M | 58.8M | 57.7M | 48.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revolution Medicines is a strong investment it is important to analyze Revolution Medicines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revolution Medicines' future performance. For an informed investment choice regarding Revolution Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revolution Medicines. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Revolution Stock refer to our How to Trade Revolution Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revolution Medicines. If investors know Revolution will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revolution Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.66) | Revenue Per Share 0.005 | Quarterly Revenue Growth (0.95) | Return On Assets (0.29) | Return On Equity (0.47) |
The market value of Revolution Medicines is measured differently than its book value, which is the value of Revolution that is recorded on the company's balance sheet. Investors also form their own opinion of Revolution Medicines' value that differs from its market value or its book value, called intrinsic value, which is Revolution Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revolution Medicines' market value can be influenced by many factors that don't directly affect Revolution Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revolution Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revolution Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revolution Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.